Neurofibromatosis Preclinical Consortium (NFPC)

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2007
  • Initiating Organization: Children's Tumor Foundation
  • Initiator Type: Nonprofit foundation
  • Disease focus:
  • Location: North America


In 2007, the Children’s Tumor Foundation (CTF) invested $4 million to launch the Neurofibromatosis Preclinical Consortium (NFPC) to test candidate drug therapies for neurofibromatosis in NF1 and NF2 models; compare the responses of different NF tumors to the same drug; and identify candidate clinical therapies. Through a competitive process, six centers were selected — four for NF1 and two for NF2. NFPC has successfully established a preclinical drug testing pipeline and has formed productive collaborations with industrial partners. NFPC has been CTF’s most significant research investment to date.

Consortium History

2008-2013: Project duration

Structure & Governance

NFPC External Advisory Board (EAB):
Jay Gibbs, Ph.D. (chair), AstraZeneca Pharmaceuticals
Gideon E. Bollag, Ph.D., Plexxikon Inc.
Sara A. Courtneidge, Ph.D., The Burnham Inst. for Medical Research
Michael J. Morin, Ph.D., Oncovia, Inc.
Frank McCormick, Ph.D., University of California, San Francisco
Edward Stern, Esq.,  legal counsel to the CTF Medical Advisory Committee
Tona Gilmer, Ph.D., GSK Pharmaceuticals
EAB Emeritus Members:

Larry Gelbert, Ph.D., Eli Lilly and Company
Filippo G. Giancotti, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center
Janet M Hock, BDS, Ph.D., Maine Institute for Human Genetics and Health
Christopher L. Moertel, M.D., Children’s Hospitals and Clinics of Minnesota
Roger J. Packer, M.D., Children’s National Medical Center


Children’s Tumor Foundation invested $4 million to launch NFPC.

Sponsors & Partners

Cincinnati Children’s Hospital Medical Center

Fox Chase Cancer Center

Harvard Medical School/Brigham & Women’s Hospital

Indiana University

Ohio State University

University of California, San Francisco

Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.